Phenobarbital + phenytoin

Generic Medicine Info
Hypersensitivity; acute intermittent porphyria; severe renal and hepatic disorders; severe myocardial damage, AV block; respiratory depression.
Special Precautions
Elderly; seriously ill patients; patients doing work requiring mental alertness and unimpaired reflexes; lactation, pregnancy; children; history of alcohol or drug abuse; hepatic and renal impairment; depression and suicidal tendencies. Patients and carers should be counselled how to recognise symptoms of blood or skin disorders and to seek medical attention. Normal therapeutic levels of phenytoin: 20-40 mcg/ml. Phenobarbital and phenytoin may increase vitamin D requirements.
Adverse Reactions
Sedation, depression, irritation, aggressiveness, confusion, paradoxical excitation in children, rash, dyskinesia, macrocytic anaemia, thyroiditis, vertigo, nystagmus, ataxia, diplopia and gingival hypertrophy.
Potentially Fatal: Agranulocytosis, aplastic anaemia, exfoliative dermatitis (Stevens Johnson syndrome), severe hepatitis and leucopenia.
Drug Interactions
Phenytoin and phenobarbital may alter each other's metabolism. Both reduce levels of abacavir, amprenavir, TCAs, aprepitant, apripiprazole, carbamazepine (phenytoin levels reduced), valproate, clonazepam, lamotrigine, tacrolimus (phenytoin levels may increase) and theophylline. Phenytoin and phenobarbital may decrease effects of systemic corticosteroids, ciclosporin, coumarins, digitoxin, oestrogens and progestogens. Valporate may increase levels of phenobarbitone and phenytoin (levels may conversely increase). Antipsychotics, TCAs, SSRIs and TCA related antidepressants may antagonise effects of phenytoin and phenobarbital. Phenytoin reduces levels and effects of bupropion, busulfan, caspofungin, digoxin, disopyramide, eplerenone, imatinib, levodopa, mirtazapine and furosemide. Levels of phenytoin may be reduced by antacids (separate doses by a couple of hr), sucralfate, carbamazepine and theophylline. Phenytoin levels may be affected by benzodiazepines and ciprofloxacin. Levels of phenytoin may be increased by cimetidine, clarithromycin, diazepam, fluoxetine, fluconazole, fluvoxamine, itraconazole, ketoconazole, metronidazole, sulphonamide, topiramate (may reduce topiramate levels), trimethoprim (antifolate effect) and amiodarone (interaction may continue for wk or mth. Phenytoin effects may be enhanced by influenza vaccine, esomeprazole and NSAIDs. Increased risk of withdrawal symptoms when phenytoin is used with methadone. Pyrimethamine may antagonise phenytoin effects. Phenytoin may increase antifolate effect of methotrexate. Concomitant use of phenobarbital and carbonic anhydrase inhibitors may increase risk of osteomalacia. Chlorpromazine and phenobarbital levels may be reduced when given together. Phenobarbital reduces effects of dihydropyridine calcium channel blockers, diltiazem, felodipine, nelfinavir, verapamil, griseofulvin, doxycycline, disopyramide, thyroid hormones, tibolone, haloperidol and mianserin. Phenobarbital reduces levels of chloramphenicol, indinavir, rifampicin, telithromycin (avoid 2 wk before or after phenobarbital), ethosuximide, itraconazole and voriconazole (avoid concomitant use). Folates may decrease phenobarbital levels. Methylphenidate may increase phenobarbital levels.
CIMS Class
ATC Classification
N03AB02 - phenytoin ; Belongs to the class of hydantoin derivatives antiepileptics.
N03AA02 - phenobarbital ; Belongs to the class of barbiturates and derivatives antiepileptics.
Disclaimer: This information is independently developed by CIMS based on phenobarbital + phenytoin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in